CA2421723A1 - Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci - Google Patents

Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci Download PDF

Info

Publication number
CA2421723A1
CA2421723A1 CA002421723A CA2421723A CA2421723A1 CA 2421723 A1 CA2421723 A1 CA 2421723A1 CA 002421723 A CA002421723 A CA 002421723A CA 2421723 A CA2421723 A CA 2421723A CA 2421723 A1 CA2421723 A1 CA 2421723A1
Authority
CA
Canada
Prior art keywords
stat3
cells
compound
leu
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002421723A
Other languages
English (en)
Inventor
Hua Yu
Drew Pardoll
Richard Jove
William Dalton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
Johns Hopkins University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2421723A1 publication Critical patent/CA2421723A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés de modulation, c.-à-d. ayant une action agoniste ou antagoniste sur l'activité de signalisation de Stat3 (transducteur de signal et activateur de transcription3), utiles en thérapie génique. L'inhibition et/ou l'activation de la signalisation de Stat3 constitue une méthode efficace de modulation de l'angiogenèse et de la réaction immunitaire pour traiter et/ou prévenir l'inflammation, les infections, les affections immunitaires et l'ischémie.
CA002421723A 2000-09-08 2001-09-10 Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci Abandoned CA2421723A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23121200P 2000-09-08 2000-09-08
US60/231,212 2000-09-08
PCT/US2001/028254 WO2002020032A1 (fr) 2000-09-08 2001-09-10 Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci

Publications (1)

Publication Number Publication Date
CA2421723A1 true CA2421723A1 (fr) 2002-03-14

Family

ID=22868214

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002421723A Abandoned CA2421723A1 (fr) 2000-09-08 2001-09-10 Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci

Country Status (3)

Country Link
EP (1) EP1324763A4 (fr)
CA (1) CA2421723A1 (fr)
WO (1) WO2002020032A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1146869A2 (fr) 1999-01-27 2001-10-24 University Of South Florida Inhibition de la transduction du signal par la stat3 pour une therapie anticancereuse chez l'homme
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US7951374B2 (en) 2004-12-14 2011-05-31 University Of South Florida Methods for inhibiting STAT3 signaling in immune cells
WO2010118309A2 (fr) 2009-04-10 2010-10-14 Board Of Regents, The University Of Texas System Inhibiteurs du stat3 et leurs utilisations
KR102546501B1 (ko) * 2016-07-19 2023-06-21 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Stat3를 타겟으로 하는 종양용해성 바이러스

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1146869A2 (fr) * 1999-01-27 2001-10-24 University Of South Florida Inhibition de la transduction du signal par la stat3 pour une therapie anticancereuse chez l'homme
US6159694A (en) * 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
US6235873B1 (en) * 1999-07-31 2001-05-22 The Rockefeller University Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes

Also Published As

Publication number Publication date
WO2002020032A1 (fr) 2002-03-14
EP1324763A1 (fr) 2003-07-09
EP1324763A4 (fr) 2007-10-31
WO2002020032A9 (fr) 2003-03-20

Similar Documents

Publication Publication Date Title
US20070072822A1 (en) STAT3 agonists and antagonists and therapeutic uses thereof
Mu et al. IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease
Mano et al. Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery
Ghoreschi et al. Janus kinases in immune cell signaling
US6475987B1 (en) Tall-1 receptor homologues
Sennello et al. Lrp5/β-catenin signaling controls lung macrophage differentiation and inhibits resolution of fibrosis
JP5647577B2 (ja) ニュールツリン産物を含む薬剤
US20090038022A1 (en) IGF-1 Novel peptides
US20210079392A1 (en) Inhibition of mir-22 mirna by apt-110
US20040224389A1 (en) Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US6312684B1 (en) Method of inducing resistance to tumor growth
JP2003512304A (ja) 医薬組成物および分泌フリズル化関連タンパクを用いる方法
JP2006505266A (ja) 幹細胞の増幅因子
JP2005504010A (ja) 成長ホルモンおよびｆｏｘｍ１ｂを用いた肝臓疾患および肝臓損傷の処置方法
MX2014000872A (es) Modulacion de quimiocina selectiva de tumor.
CA2421723A1 (fr) Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci
EP3884055B1 (fr) Construction de gènes suicides doubles et inductibles et son utilisation dans la thérapie génique
JP2003505058A (ja) 治療法および薬剤スクリーニング法
US20040109844A1 (en) Methods of treating age-related defects and diseases
WO2003061684A2 (fr) Nouvelles compositions pharmaceutiques pour le traitement d'une tumeur
JPH11514884A (ja) 腫瘍にあるサイクリンｇ１の発現
JP2002533402A (ja) 癌を処置するためおよび樹状細胞の走化性を媒介するための方法
JP4252446B2 (ja) Ａｂｉｎにより媒介される肝炎防護
JP2007516984A (ja) 治療用物質およびそのための用途
US6268350B1 (en) Polynucleotides for inhibiting metastasis and tumor cell growth

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20110110